PAM2L Biotechnologies

PAM2L Biotechnologies (柏垠生物) is a Chinese biotech startup developing bio-based materials through a dual-engine platform combining synthetic biology and machine learning, described as "BT-IT" . The company was co-founded in March 2021 by Zhong Chao, a researcher at the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences, and his university classmate Cui Junfeng . Its focus is on protein and polysaccharide innovations, with product pipelines including adhesive proteins, bacterial cellulose, and mucopolysaccharides .

The company has raised multiple rounds since its founding. 5Y Capital led its ~$5 million angel round in December 2021 , followed by a tens-of-millions RMB angel+ round led by Tiantu Capital in mid-2022 . In January 2023, it closed a Pre-A round of over 100 million RMB jointly led by Yunqi Capital, Woyong Fund, and Fuhua Capital, with Cornerstone Capital and Yayi Capital participating . The Pre-A proceeds were directed toward R&D platform upgrades and capacity expansion . Elsewhere's corpus does not cover developments after early 2023.